More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
AUM
$457354317
P/E ratio
--
Dividend yield
11.691%
Expense ratio
1.38%
Beta
0.777126
Previous close
$18.28
Today's open
$18.51
Day's range
$17.76 - $19.09
52 week range
$15.66 - $22.67
Headquarters
US
Exchange
New York Stock Exchange
Issue type
Common Stock
Industries
Health
AMGN
Amgen Inc
4%
3.8%
INSM
Insmed Inc
3.1%
QURE:AS
Uniqure N.V. Ordinary Shares
3%
2.6%
PCVX
Vaxcyte Inc
2.6%
2.5%
2.3%
Analysis Of Abrdn Healthcare Investors (HQL): The Fund Is Currently Overvalued
abrdn Healthcare Investors (HQL) is a closed-end fund focused on healthcare and biotechnology, offering capital appreciation and high current income. HQL currently trades at a -1.9% discount to NAV, far narrower than its historical average, with a one-year z-score of 3.06, indicating overvaluation. The fund boasts a 13.45% dividend yield, but this exceeds long-term asset returns, raising sustainability concerns during market stagnation.
Seeking Alpha • Nov 2, 2026

10 Best CEFs This Month: Average Yield Of 10% (September 2026)
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 10% plus yield and nearly a 6% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.
Seeking Alpha • Sep 26, 2026

HQL: The Rally That Makes Growth Harder (Rating Downgrade)
abrdn Life Sciences Investors Fund is downgraded to Hold after a 57.6% total return and a rally driven by sector-wide capital rotation. HQL's 12.5% yield is supported by strong net realized gains, but its reliance on these gains and a higher distribution limit future price appreciation. The fund trades at a 5.95% discount to NAV, the lowest in three years, making new accumulation less attractive amid potential sentiment cooling.
Seeking Alpha • Sep 15, 2026

10 Best CEFs This Month: Average Yield Of Near 10% (August 2026)
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 10% yield and nearly 5% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.
Seeking Alpha • Aug 29, 2026

10 Best CEFs This Month: Average Yield Of Near 10% (July 2026)
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 10% plus yield and nearly 7.7% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.
Seeking Alpha • Jul 25, 2026

HQL: Attractive Outlook With Growth Of GLP-1 Market
I maintain a buy rating on abrdn Life Sciences Investors Fund (HQL), which trades at an 8.49% discount to NAV and offers a 12.6% yield. HQL is positioned to benefit from the accelerating GLP-1 market, with top holdings in high-growth biotech names and a portfolio heavily weighted to biotechnology. While total returns have been competitive, HQL's high distributions come at the expense of capital appreciation, making it best suited for income-focused investors.
Seeking Alpha • May 19, 2026

How To Invest $100,000 Today: 5 Strategies For Success
The market environment is challenging, to say the least. We discuss how one should invest in today's market. The article presents five different investment strategies, including a fixed-income strategy, high-income strategy, sleep-well-at-night strategy, growth-focused strategy, and the Near-Perfect Portfolio strategy. Selecting a strategy aligned with personal risk tolerance and sticking to it through cycles is critical for long-term success.
Seeking Alpha • Apr 25, 2026

10 Best CEFs This Month: Average Yield Of 10% (March 2026)
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 10% plus yield and 10.8% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.
Seeking Alpha • Mar 29, 2026

10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.
Seeking Alpha • Feb 28, 2026

How We're Playing ‘AI 2.0' For Big Dividend Payouts
If you're wondering whether the rally in tech stocks is fading, well, it is.
Forbes • Jan 31, 2026

¹ Disclosures

Open an M1 investment account to buy and sell abrdn Life Sciences Investors Shares of Beneficial Interest commission-free¹. Build wealth for the long term using automated trading and transfers.